Akura Medical

Executive Summary

Akura Medical is a San Diego-based private medical device company dedicated to transforming the treatment of venous thromboembolism (VTE) through its innovative Katana Thrombectomy System. Founded in 2018, the company addresses the critical need for rapid and efficient removal of blood clots in VTE patients, aiming to improve procedural outcomes and reduce complications. The Katana platform integrates advanced intraoperative feedback mechanisms to enhance procedural speed, accuracy, and efficiency, positioning it as a potential game-changer in thrombectomy care. With a focused mission and a strong intellectual property foundation, Akura Medical is poised to capture a significant share of the growing VTE treatment market. Akura Medical's differentiation lies in its emphasis on real-time feedback, which allows physicians to optimize clot removal, potentially reducing procedure times and improving patient recovery. The VTE market, valued at over $2 billion, is expanding due to increasing awareness and diagnosis rates. While the company is at a relatively early stage, its technology addresses clear unmet needs in safety and efficacy. Success will depend on clinical validation, regulatory clearance, and commercialization strategy. The company's private status and lack of public funding details suggest it may be preparing for a significant capital raise or partnership to advance its pipeline. Overall, Akura Medical represents a promising opportunity in the medical device sector, with potential for substantial impact on VTE management.

Upcoming Catalysts (preview)

• Q4 2026Initiating pivotal clinical trial for Katana Thrombectomy System80% success
• Q2 2027FDA 510(k) clearance submission for Katana Thrombectomy System70% success
• Q3 2026Series A/B funding round to support clinical and regulatory milestones90% success